Enliven Therapeutics Inc. (ELVN NASDAQ) stock market data APIs
$16.8349
0.13(0.8%)
as of December 19, 2025
Try our APIs with
free plan!
Enliven Therapeutics Inc. Financial Data Overview
Price chart is built with
Anychart
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.
Prev. Close
16.8349
Open
16.8677
High
17.2351
Low
16.7423
52 wk Range
13.3-25.37
Market Cap
1 001 M
Shares Outstanding
59 347 K
EPS
-0.32
Beta
1.074
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Enliven Therapeutics Inc. (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enliven Therapeutics Inc. data using free add-ons & libraries
Get Enliven Therapeutics Inc. Fundamental Data
Enliven Therapeutics Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -111 972 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-12
- EPS/Forecast: -0.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enliven Therapeutics Inc. News
New
ELVN Makes Notable Cross Below Critical Moving Average
In trading on Tuesday, shares of Enliven Therapeutics Inc (Symbol: ELVN) crossed below their 200 day moving average of $20.03, changing hands as low as $17.31 per share. Enliven Therapeutics Inc shar...
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance?
Key Points New York City-based Commodore Capital bought nearly 4.1 million shares, increasing portfolio value by an estimated $55 million. The position represents 2.7% of 13F reportable assets under ...
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away
Key Points New York City-based Commodore Capital sold nearly 1.5 million shares of Scholar Rock, a net position change of about $51 million. The transaction value was approximately 2.5% of Commodore ...
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors
Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new positio...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
